Cardlytics, Inc. (NASDAQ:CDLX) Given Consensus Recommendation of “Reduce” by Brokerages

Shares of Cardlytics, Inc. (NASDAQ:CDLX) have been given a consensus rating of “Reduce” by the seven analysts that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation and six have issued a hold recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.92.

CDLX has been the subject of several analyst reports. Bank of America cut shares of Cardlytics from a “neutral” rating to an “underperform” rating and lowered their price target for the stock from $4.00 to $3.50 in a report on Thursday, August 15th. Northland Capmk lowered Cardlytics from a “strong-buy” rating to a “hold” rating in a report on Friday, August 16th. Lake Street Capital downgraded Cardlytics from a “buy” rating to a “hold” rating and decreased their price target for the stock from $18.00 to $5.00 in a report on Thursday, August 8th. Craig Hallum downgraded Cardlytics from a “buy” rating to a “hold” rating in a report on Thursday, August 8th. Finally, Northland Securities cut Cardlytics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $7.00 to $5.00 in a research note on Friday, August 16th.

Insiders Place Their Bets

In related news, CEO Amit Gupta sold 22,607 shares of the firm’s stock in a transaction that occurred on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total transaction of $87,036.95. Following the transaction, the chief executive officer now owns 178,519 shares in the company, valued at $687,298.15. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In related news, Director Scott A. Hill purchased 40,000 shares of the business’s stock in a transaction dated Monday, August 12th. The stock was acquired at an average price of $3.58 per share, for a total transaction of $143,200.00. Following the completion of the purchase, the director now directly owns 40,000 shares of the company’s stock, valued at $143,200. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Amit Gupta sold 22,607 shares of the stock in a transaction on Thursday, October 24th. The stock was sold at an average price of $3.85, for a total value of $87,036.95. Following the sale, the chief executive officer now directly owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,573 shares of company stock valued at $151,612. 4.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Cardlytics

A number of large investors have recently bought and sold shares of the company. Creative Planning increased its stake in shares of Cardlytics by 35.4% during the third quarter. Creative Planning now owns 29,537 shares of the company’s stock worth $95,000 after acquiring an additional 7,721 shares during the period. SG Americas Securities LLC purchased a new stake in Cardlytics during the third quarter worth about $45,000. Marshall Wace LLP grew its position in Cardlytics by 6.8% during the second quarter. Marshall Wace LLP now owns 814,281 shares of the company’s stock worth $6,685,000 after buying an additional 52,081 shares during the period. XTX Topco Ltd purchased a new position in Cardlytics in the second quarter valued at about $107,000. Finally, Pekin Hardy Strauss Inc. purchased a new position in Cardlytics in the second quarter valued at about $243,000. Hedge funds and other institutional investors own 68.10% of the company’s stock.

Cardlytics Stock Performance

Shares of CDLX stock opened at $4.04 on Tuesday. Cardlytics has a 52 week low of $2.89 and a 52 week high of $20.52. The firm has a 50 day moving average of $3.62 and a two-hundred day moving average of $7.14. The company has a quick ratio of 1.77, a current ratio of 1.77 and a debt-to-equity ratio of 1.01. The stock has a market capitalization of $197.08 million, a PE ratio of -0.91 and a beta of 1.67.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.12. The company had revenue of $69.64 million for the quarter, compared to the consensus estimate of $75.39 million. Cardlytics had a negative return on equity of 17.96% and a negative net margin of 50.21%. Cardlytics’s revenue was down 9.2% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.57) EPS. On average, research analysts predict that Cardlytics will post -1.72 EPS for the current fiscal year.

About Cardlytics

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.